MX9305855A - Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad. - Google Patents

Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.

Info

Publication number
MX9305855A
MX9305855A MX9305855A MX9305855A MX9305855A MX 9305855 A MX9305855 A MX 9305855A MX 9305855 A MX9305855 A MX 9305855A MX 9305855 A MX9305855 A MX 9305855A MX 9305855 A MX9305855 A MX 9305855A
Authority
MX
Mexico
Prior art keywords
tumorigenic
cell
propensity
become
latumorigenicity
Prior art date
Application number
MX9305855A
Other languages
English (en)
Inventor
Tadatsugu Taniguchi
Cheryl L Willman
Maria G Pallavicini
Hisashi Harada
Noboyuki Tanaka
Original Assignee
Tadatsugu Taniguchi
Willman C
Pallavicini M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tadatsugu Taniguchi, Willman C, Pallavicini M filed Critical Tadatsugu Taniguchi
Publication of MX9305855A publication Critical patent/MX9305855A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

La presente invención se refiere, en general, a un método paradiagnosticar células tumorígenas de mamífero o la propensión de una célulade mamífero para llegar a ser tumorígena. Adicionalmente, la presenteinvención se refiere a un CDNA o DNA genómico clonado para reducir lapropensión de una célula para llegar a ser tumorígena o suprimir elfenotipo tumorígeno de una célula; un método para reducir la propensión deuna célula para llegar a ser tumorígena o suprimir el fenotipo tumorígenode una célula; un método de tratamiento de un paciente que padece o estápredispuesto a desarrollar subsiguientemente cáncer; y un método paradiagnosticar tejido tumorígeno de un ser humano o tejido predispuesto parallegar a ser tumorígeno.
MX9305855A 1992-09-24 1993-09-23 Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad. MX9305855A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95057492A 1992-09-24 1992-09-24
US99559492A 1992-12-22 1992-12-22

Publications (1)

Publication Number Publication Date
MX9305855A true MX9305855A (es) 1995-01-31

Family

ID=27130304

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9305855A MX9305855A (es) 1992-09-24 1993-09-23 Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.

Country Status (10)

Country Link
US (2) US5652095A (es)
EP (1) EP0662976A4 (es)
JP (1) JPH08501691A (es)
CN (1) CN1051110C (es)
AU (1) AU682321B2 (es)
CA (1) CA2145412A1 (es)
HU (1) HU217688B (es)
MX (1) MX9305855A (es)
NZ (1) NZ256623A (es)
WO (1) WO1994006818A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
EP0648493A1 (en) * 1993-10-19 1995-04-19 Tadatsugu Prof. Dr. Taniguchi A method to reverse the phenotype of transformed cells by the transcription factor IRF-1
PH31414A (en) * 1994-02-24 1998-10-29 Boehringer Ingelheim Int Method of diagnosing cancer precancerous state, orsusceptibility to other forms of diseases by anal ysis of irf-1 specific rna in biopsy samples.
CN1177934C (zh) * 1997-04-28 2004-12-01 阿文蒂斯药物股份有限公司 腺病毒介导的肿瘤内投送血管生成拮抗剂用于肿瘤的治疗
TWI248365B (en) 1999-08-23 2006-02-01 Chugai Pharmaceutical Co Ltd HM1.24 antigen expression potentiators
JP4522431B2 (ja) * 2001-02-07 2010-08-11 中外製薬株式会社 造血器腫瘍の治療剤
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
JP2004529888A (ja) * 2001-02-26 2004-09-30 ゲゼルシャフト フュア ビオテヒノロジッシェ フォルシュング エムベーハー （ゲーベーエフ） インターフェロン調節因子−１／ヒトエストロゲン受容体融合タンパク質および癌を治療するためのその使用
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
EP1390075B1 (en) * 2001-04-06 2012-01-18 The University of Chicago Chemotherapeutic induction of egr-1 promoter activity in gene therapy
CN108221058A (zh) * 2017-12-29 2018-06-29 苏州金唯智生物科技有限公司 一种猪全基因组sgRNA文库及其构建方法和应用
CN108205614A (zh) * 2017-12-29 2018-06-26 苏州金唯智生物科技有限公司 一种全基因组sgRNA文库的构建系统及其应用
CA3170045A1 (en) * 2020-03-06 2021-09-10 Saumendra N. SARKAR Irf modulator-expressing oncolytic viruses for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE68929344T2 (de) * 1988-08-24 2002-07-11 Tadatsugu Taniguchi Gen-Expression regulierender Faktor
EP0631584A4 (en) * 1991-02-28 1998-07-01 Dana Farber Cancer Inst Inc DIAGNOSIS AND THERAPY OF CANCER.

Also Published As

Publication number Publication date
AU682321B2 (en) 1997-10-02
CA2145412A1 (en) 1994-03-31
CN1051110C (zh) 2000-04-05
HUT71768A (en) 1996-01-29
NZ256623A (en) 1997-04-24
US5652095A (en) 1997-07-29
HU9500841D0 (en) 1995-05-29
HU217688B (hu) 2000-03-28
AU5141793A (en) 1994-04-12
US5807836A (en) 1998-09-15
WO1994006818A1 (en) 1994-03-31
EP0662976A4 (en) 1997-04-23
EP0662976A1 (en) 1995-07-19
JPH08501691A (ja) 1996-02-27
CN1098140A (zh) 1995-02-01

Similar Documents

Publication Publication Date Title
MX9305855A (es) Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.
Blum The physiological effects of sunlight on man
Stidham et al. Survival superiority of females with melanoma: a multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome
RO93650B (ro) Procedeu pentru obtinerea unei polipeptide umane fiziologic activa
EP0625991A4 (en) IMPROVED ALPHA INTERFERON COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF FROM LEUKOCYTES OF THE HUMAN PERIPHERAL BLOOD.
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
Olckers et al. Adult muscle sodium channel α-subunit is a gene candidate for malignant hyperthermia susceptibility
Cohrs et al. Effect of vitamin E succinate and a cAMP-Stimulating agent on the expression of c-myc, N-myc and H-ras in murine neuroblastoma cells
PT651636E (pt) Quimioterapia contra o cancro
Golan et al. Increased photosensitivity to near-ultraviolet light in murine SLE.
Blitzer et al. Blood pressure and hemoglobin concentration: multivariate analysis of local control after irradiation for head and neck cancer
Mivechi et al. Lack of development of thermotolerance in early progenitors of murine bone marrow cells
Jakobsson et al. Fractionation scheme with low individual tumour dose and high total dose
Rolfs et al. Guiding the unconscious: The process of poem selection for poetry therapy groups.
DE69113802T2 (de) Anwendung von beta-alethin in zellkultur und therapie.
Bodansky Mechanism of action of methylene blue in treatment of methemoglobinemia
Giannelli et al. Xeroderma pigmentosum and medulloblastoma: chromosomal damage to lymphocytes during radiotherapy
Hendry Re-irradiation of mouse skin: similarity of dose reductions for healing and macrocolony endpoints
Zankl et al. Quantitative studies on the arrangement of human metaphase chromosomes: VI. The association pattern of acrocentric chromosomes in patients with trisomy 13
Kakar et al. Solitary plasmacytoma larynx
Christensen et al. Unwanted side effects and optimization of phototherapy
DK0782452T3 (da) Cellevækstregulator
Berkowitz Family therapy and adult mental illness: Schizophrenia and depression.
Walker et al. Nasolabial flap reconstruction for carcinoma of the lower lip: An eleven year follow-up study
TAKATSUKA et al. SURGICAL TREATMENT OF EARLY BREAST CANCER

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees